BACKGROUND The first-in-class and most widely commercially available bioresorbable scaffold (BRS) Absorb has strut thickness of 150 microns, far exceeding those of contemporary drug-eluting stents. As such, it has potential for delivery challenges and higher thrombogenicity. As such, decreasing the BRS strut thickness with no adverse effect on its biomechanics seems desirable. The aim of the study was
BACKGROUND The first-in-class and most widely commercially available bioresorbable scaffold (BRS) Absorb has strut thickness of 150 microns, far exceeding those of contemporary drug-eluting stents. As such, it has potential for delivery challenges and higher thrombogenicity. As such, decreasing the BRS strut thickness with no adverse effect on its biomechanics seems desirable. The aim of the study was to assess safety and efficacy of a novel thin strut (100 mm) sirolimus eluting BRS (MeRes100, Meril Life Sciences, Gujarat, India) in porcine coronary arteries.
METHODS A total of 34 coronary segments of 14 healthy swine were implanted with 24 thin strut sirolimus eluting MeRes100 BRS and 10 Absorb scaffolds at 110% overstretch. To date, angiographic and optical coherence tomography (OCT) imaging were performed after 1 and 3 months (MeRes100 n¼19 and Absorb n¼8 at each time point). Of the entire cohort, 3 animals were euthanized at each time point and coronary segments were harvested for histological evaluation.
RESULTS
The animals in both groups were comparable with regard to weight, clinical status, baseline vessel size and procedural characteristics. All procedures were completed with no complications. At the implantation procedure there was no statistical difference in angiographic, minimal lumen diameter (MLD)-based percent acute recoil between MeRes100 and Absorb (respectively: 13% AE 7% vs. 10% AE 5% p¼0.18). OCT evaluation demonstrated no differences in metrics of neointimal proliferation in MeRes100 when compared to Absorb at 1and 3-month follow up. Angiographic results corresponded to OCT and showed similar results without statistical differences in MLD and late loss at both time points. OCT and angiographic results are summarized in the table. Histological analysis at 1-month follow up revealed comparable results in MeRes100 and Absorb in % area stenosis (respectively: 28.7 AE 12.6% vs. 27.3AE2.5% p¼0.86), neointimal area (respectively 1.77AE0.82 vs. 1.95AE0.35 mm2; p¼0.22) and in qualitative parameters of vascular healing. Three-month histological results will be available by the time of the meeting.
CONCLUSIONS The novel sirolimus-eluting BRS with thinner struts and hybrid cell design showed similar radial strength and equivalent inhibition of neointimal proliferation when compared to the benchmark Absorb BVS up to 90 days in normal porcine coronary arteries. Registry in Japan) score was developed to predict the probability of successful guidewire crossing within 30 minutes. However, guidewire crossing alone does not ensure final success of CTO PCI. We therefore sought to develop a novel parsimonious scoring system to estimate the likelihood of technical success.
METHODS We examined 781 CTO percutaneous coronary interventions (PCI) performed using the "hybrid" approach and included in the Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO). To develop the "PROGRESS CTO" score we analyzed clinical and angiographic parameters using a derivation and validation cohort (2:1 sampling ratio). Variables with strong association with technical failure in multivariable analysis were assigned 1 point and a 4-point score was developed from summing all points. The PROGRESS CTO score was subsequently compared with the J-CTO score in the validation cohort. CONCLUSIONS The PROGRESS CTO score is a novel useful tool for estimating technical success in CTO PCI performed using the hybrid approach. BACKGROUND The coronary sinus (CS) Reducer is a recently introduced device to treat patients with severe anginal symptoms who are refractory to optimal medical therapy and not amenable for conventional revascularization. We aimed to assess the safety and efficacy of the CS Reducer in a "real world" cohort of patients with refractory angina.
METHODS This is a single center retrospective registry. Patients with severe anginal symptoms, objective evidence of myocardial ischemia using any modality and without options for conventional revascularization were regarded eligible for CS Reducer implantation. RESULTS Overall, the minimum lumen area (MLA) of the lesions ranged from 1.0 to 7.4 mm2 (median 2.1 mm2). DIB significantly correlated with both FFR and iFR (Figure) , which was also confirmed in a subset of lesions with small MLA (defined as < the median value). Receiver operating characteristic (ROC) curve analyses identified the best cut-off value as 7.25 of DIB for predicting FFR 0.8 (sensitivity 100%; specificity 88%; positive predictive value 86%; negative predictive value 100%, accuracy 93%), and 9.14 of DIB for predicting iFR 0.89 (sensitivity 100%; specificity 79%; positive predictive value 61%; negative predictive value 100%; accuracy 84%).

